The AUA is working to procure a $10 million dedicated research program, or line item, for bladder cancer within the Congressionally Directed Medical Research Programs (CDMRP). Last week, the AUA, in collaboration with the Bladder Cancer Advocacy Network, met with the offices of Representative Julia Brownley (D-CA-26), Representative Cheri Bustos (D-IL-17), Representative Gregory F. Murphy (R-NC-3), Representative John Rutherford (R-FL-4), and Representative Neal Dunn (R-FL-2) to discuss the AUA’s Fiscal Year (FY) 2022 research appropriation funding priorities around the creation of a bladder cancer research program within CDMRP. CDMRP is a major funder of scientific research administered by the Department of Defense. CDMRP is known for funding high risk, high reward projects and for allowing patients to play a role in deciding what research will be funded.
Both prostate cancer and kidney cancer have their own line items with dedicated funding Congress votes to approve yearly. Bladder cancer currently is funded under a larger umbrella program called the Peer Reviewed Cancer Research Program. The AUA’s goal is to ensure in fiscal year 2022, bladder cancer receives its own line item at $10 million. While this is a significant request, Congressional offices have given us positive feedback and we are hopeful the need for bladder cancer funding will be recognized this year.